Necitumumab
- Generic Name
- Necitumumab
- Brand Names
- Portrazza
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 906805-06-9
- Unique Ingredient Identifier
- 2BT4C47RUI
- Background
Necitumumab is an intravenously administered recombinant monoclonal IgG1 antibody used in the treatment of non-small cell lung cancer (NSCLC) as an EGFR antagonist. It functions by binding to epidermal growth factor receptor (EGFR) and prevents binding of its ligands, a process that is involved in cell proliferation, metastasis, angiogenesis, and malignant p...
- Indication
Necitumumab is approved for use in combination with cisplatin and gemcitabine as a first-line treatment for metastatic squamous non-small cell lung cancer (NSCLC). It is not indicated for treatment of non-squamous NSCLC.
- Associated Conditions
- Metastatic Non-Small Cell Lung Cancer
- Associated Therapies
- -
Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)
- Conditions
- Interventions
- First Posted Date
- 2019-05-10
- Last Posted Date
- 2024-07-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 248
- Registration Number
- NCT03944772
- Locations
- 🇸🇪
Research Site, Stockholm, Sweden
QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed
- Conditions
- Interventions
- Drug: Aldoxorubicin HClBiological: ETBX-011Biological: ETBX-021Biological: ETBX-051Biological: ETBX-061Biological: GI-4000Biological: GI-6207Biological: GI-6301Biological: haNK for infusionDrug: AvelumabDrug: bevacizumabDrug: CapecitabineDrug: CetuximabDrug: CisplatinDrug: CyclophosphamideDrug: FluorouracilDrug: LeucovorinDrug: nab-PaclitaxelDrug: NecitumumabProcedure: SBRTBiological: N-803
- First Posted Date
- 2017-12-29
- Last Posted Date
- 2024-08-05
- Lead Sponsor
- ImmunityBio, Inc.
- Target Recruit Count
- 4
- Registration Number
- NCT03387111
- Locations
- 🇺🇸
Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States
A Study of Gemcitabine-Carboplatin Plus Necitumumab (LY3012211) in Chemotherapy-Naïve Participants With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- Interventions
- First Posted Date
- 2016-10-21
- Last Posted Date
- 2019-09-27
- Lead Sponsor
- Eli Lilly and Company
- Registration Number
- NCT02941601
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., London, United Kingdom
🇺🇸Fairview Southdale Oncology Clinic, Edina, Minnesota, United States
A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-06-03
- Last Posted Date
- 2024-02-05
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 29
- Registration Number
- NCT02789345
- Locations
- 🇪🇸
Hospital Universitario Ramon y Cajal, Madrid, Spain
🇨🇳For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taipei city, Taiwan
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor
- Conditions
- Interventions
- First Posted Date
- 2015-07-14
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 138
- Registration Number
- NCT02496663
- Locations
- 🇺🇸
Emory Saint Joseph's Hospital, Atlanta, Georgia, United States
🇺🇸UCHealth University of Colorado Hospital, Aurora, Colorado, United States
🇺🇸MedStar Georgetown University Hospital, Washington, District of Columbia, United States
A Study of the Combination of Necitumumab (LY3012211) and Pembrolizumab (MK3475) in Participants With NSCLC
- Conditions
- Interventions
- First Posted Date
- 2015-05-22
- Last Posted Date
- 2020-10-05
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 71
- Registration Number
- NCT02451930
- Locations
- 🇺🇸
Tennessee Oncology PLLC, Nashville, Tennessee, United States
🇯🇵For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Sunto-Gun, Japan
🇪🇸For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Valencia, Spain
A Study of LY3023414 and Necitumumab in Squamous Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-05-13
- Last Posted Date
- 2020-12-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 31
- Registration Number
- NCT02443337
- Locations
- 🇺🇸
Southern Cancer Center, P.C., Mobile, Alabama, United States
🇺🇸Comprehensive Cancer Care and Research Institute of Colorado, Englewood, Colorado, United States
🇺🇸Chattanooga Oncology Hematology, Chattanooga, Tennessee, United States
A Study of Necitumumab and Abemaciclib in Participants With Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- Interventions
- First Posted Date
- 2015-04-08
- Last Posted Date
- 2020-07-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 66
- Registration Number
- NCT02411591
- Locations
- 🇪🇸
Hospital Universitario Ramon y Cajal, Madrid, Spain
🇫🇷For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT-5 hours, EST), or speak with your personal physician., Villejuif, France
🇪🇸For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sevilla, Spain
A Study of Nab-Paclitaxel and Carboplatin Plus Necitumumab (LY3012211) in Participants With Stage IV Squamous NSCLC
- Conditions
- Interventions
- First Posted Date
- 2015-03-19
- Last Posted Date
- 2020-11-19
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 54
- Registration Number
- NCT02392507
- Locations
- 🇺🇸
Florida Hospital Cancer Institute, Orlando, Florida, United States
A Study of Gemcitabine-Cisplatin Chemotherapy Plus Necitumumab in the First-Line Treatment of Participants With Squamous Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-02-11
- Last Posted Date
- 2016-06-27
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 61
- Registration Number
- NCT01788566
- Locations
- 🇨🇳
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taipei, Taiwan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.